Ravid 1993

Methods	Country: Israel Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: No Follow‐up period: 5 years Loss to follow‐up: 8
Participants	Inclusion criteria Age: < 50 years DM: Type 2 with duration of less than 10 years BMI: < 27 kg/m² BP: Normal on 2 consecutive examinations (BP < 130/90 mm Hg; MAP < 107 mm Hg) SCr: < 1.4 mg/dL AER: 30‐300 mg/24 h on 2 consecutive visits without evidence of UTI Enalapril group Number: 49 Age: 43.5 (3) Sex (M/F): 21/28 Placebo group Number: 45 Age: 44.8 (3.5) Sex (M/F): 21/24 Exclusion criteria Evidence of systemic, renal, cardiac or hepatic diseases
Interventions	Enalapril group 10 mg/d Placebo group Co‐interventions Long‐acting nifedipine
Outcomes	AER Renal function Glycaemic control BP
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear